| DB ID | MyCo_1081 |
| Title | Aspergillus calidoustus and Talaromyces columbinus infections in chronic graft-versus-host disease |
| Year | 2024 |
| PMID | 39227451 |
| Fungal Diseases involved | Aspergillus calidoustus infection |
| Associated Medical Condition | graft-versus-host disease (GvHD) |
| Genus | Aspergillus |
| Species | calidoustus |
| Organism | Aspergillus calidoustus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | A 30-year-old man with chronic myeloid leukaemia resis- tant to tyrosine kinase inhibitors underwent myeloablative haploidentical HSCT after conditioning consisted of thio- tepa 10 mg/Kg, busulfan 9.6 mg/kg, fludarabine 150 mg/m2 |
| Cohort No. | 1 |
| Age Group | 30 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | GM Assay, BDG Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
